The estimated Net Worth of Julianbaker Bros Advisors L... is at least $12.6 Million dollars as of 29 October 2012. Julianbaker L owns over 4,722,666 units of XOMA Royalty stock worth over $12,579,314 and over the last 12 years Julianbaker sold XOMA stock worth over $0.
Julianbaker has made over 1 trades of the XOMA Royalty stock since 2012, according to the Form 4 filled with the SEC. Most recently Julianbaker bought 4,722,666 units of XOMA stock worth $14,167,998 on 29 October 2012.
The largest trade Julianbaker's ever made was buying 4,722,666 units of XOMA Royalty stock on 29 October 2012 worth over $14,167,998. On average, Julianbaker trades about 4,722,666 units every 0 days since 2012. As of 29 October 2012 Julianbaker still owns at least 463,839 units of XOMA Royalty stock.
You can see the complete history of Julianbaker L stock trades at the bottom of the page.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: